Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin cream versus Soolantra and vehicle in papulopustular rosacea
2023-505897-13-00Phase 3Authorised
- Sponsor
- Dermapharm
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivermectin in papulopustular rosacea (3 arms), sponsored by Dermapharm. Primary endpoint: Percent change in inflammatory lesion count at end of treatment. Planned start Dec 2024; status: authorised.
02
Drugs
ivermectin
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on 2023-505897-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505897-13-00.